FDA Puts Opioids, Compounding, Stem Cells at Forefront of Enforcement Efforts
By Zachary Brennan -
Published 06 December 2017
The US opioid epidemic, drug compounding and the proliferation of stem cell clinics selling unproven treatments were highlighted as some of the focal points for US Food and Drug Administration (FDA) enforcement efforts last year and next year, officials said Wednesday at the Food and Drug Law Institute’s litigation and compliance conference in Washington, D.C.
Categories: News, US, FDA, Biologics and biotechnology, Drugs, Government affairs
Tags: opioids, FDA enforcement, FDA compliance, FDLI, stem cells